Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...

Despite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. | For ...

Workers at AbbVie’s manufacturing facility in Carrigtwohill, Ireland—one of six plants the Illinois drugmaker runs in the ...

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and ...

Famar, a portfolio company of the private equity firm of MidEuropa, is set to acquire a sterile manufacturing facility in ...

Mayne Pharma is in trouble with the FDA. The agency accused Mayne of giving a misleading impression of the risks of its oral ...

With massive social media hype around its intricate world-building and steamy love scenes, perhaps no literary genre has made ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...